American Breast Cancer Foundation
The American Breast Cancer Foundation's (ABCF) mission is to provide financial assistance for breast cancer screenings and diagnostic tests for uninsured and underserved individuals, regardless of age or gender.
The goal of the American Breast Cancer Foundation (ABCF) is to provide support and resources to clients who call us when they have nowhere else to turn. Due to disparities in breast cancer mortality nationwide, low socioeconomic status is a risk factor for negative breast cancer outcomes. ABCF works to extend the reach of the rescue by providing financial assistance for potentially lifesaving screenings and diagnostic tests.
By educating individuals about the importance of screenings, which facilitate diagnosis and treatment, ABCF works to achieve equality in breast cancer outcomes. Since its establishment, ABCF has provided financial assistance for mammograms and ultrasounds to more than 19,000 clients, regardless of age or gender.
For many years, the flagship programs of the American Breast Cancer Foundation have been the Breast Cancer Assistance Program and the Community Partnership Program. This year, a newly developed Community Advocacy Program is poised to kick off.
These programs, individually and combined, are crucial if a difference is to be made in population disparities in cancer prevention and health promotion. Research findings suggest that interventions aimed at reducing racial/ethnic disparities in cancer detection and racial/ethnic disparities in cancer treatment have the potential to influence overall differences in outcomes. It is ABCF programs' focus to reduce this disparity, and to improve survival rates of clients served.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
